MDI propellant maker Koura has announced the launch of HFA-152a development and filling services at the company’s facilities in Chester, UK. Koura (formerly Mexichem) first announced the possibility of using 152a as a low global warming potential (GWP) propellant for metered dose inhalers in 2016.
In December 2019, Chiesi announced that it planned to bring a Zephex 152a inhaler to market by the end of 2025, and in February 2020, Koura said that the FDA had cleared that it was initiating clinical trials of 152a. Koura announced a “multimillion-pound sterling investment” in a new cGMP production facility for Zephex HFA 152a in June 2020 and now says that it anticipates a license to manufacture investigational medicinal products in 2022 to allow for clinical trial manufacturing.
Read the Koura press release.
